ArticleAnnals of vascular surgery2025
Sex Differences in Platelet Response to Common Antiplatelet Medications.
Article in Annals of vascular surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundSex differences in platelet aggregation among peripheral artery disease patients are not well characterized. This study aimed to evaluate the impact of antiplatelet therapy on platelet reactivity by sex.
methodsA prospective cohort study was conducted at a single large tertiary center on patients with peripheral artery disease undergoing revascularization between 2020 and 2024. Patients were stratified based on antiplatelet therapy (mono antiplatelet therapy [MAPT], or dual antiplatelet therapy [DAPT]), with DAPT including aspirin and clopidogrel/ticagrelor. Coagulation profiles, using thromboelastography (TEG) and platelet mapping, were assessed preoperatively and postoperatively. The Mann-Whitney U test was conducted to assess differences in platelet function between sexes. Linear regression models were used to assess the potential confounding effect of sex. Mediation analysis was also performed to determine if sex mediated the treatment's effect on TEG parameters.
resultsOf the 261 patients analyzed, 35.2% were women, 88.9% were Caucasian, and 74.1% were on MAPT. Women in the MAPT group had higher fibrinogen-related clot strength (coagulation factor fibrinogen maximum amplitude: 25.5 mm vs. 23.3 mm, P < 0.002), greater platelet aggregation (93.0% vs. 86.9%, P = 0.009), and lower platelet inhibition (3.9% vs. 13.2%, P = 0.009), whereas no sex differences were observed in the DAPT group. Sex neither confounded nor mediated the effect of antiplatelet therapy on TEG parameters.
conclusionSex differences in platelet reactivity were observed in the MAPT group, suggesting that more aggressive antiplatelet therapy in women may help reduce this disparity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.